此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Supplementation of a Leucine-Enriched Dairy Protein Blend

2020年2月6日 更新者:Stuart Phillips、McMaster University

Supplementation of a Leucine-Enriched Dairy Protein Blend: Effects on Plasma Amino Acids in Older Adults

It is well known that dietary protein is a powerful transient stimulator of the muscle protein synthetic rate (MPS) whereby changes in MPS in response to feeding may be regulated by specific downstream target proteins of mammalian target of rapamycin signaling, such as S6K1, rpS6, and eIF2B. A meal deficient in protein, however, does not increase the rate of MPS because a rise in the bioavailability of amino acids does not occur. In addition, the source of dietary proteins has been shown to impact postprandial blood levels of amino acids. The concept that certain types of proteins are "fast acting" or "slow acting" has been shown to affect the postprandial profile of amino acids appearing in the systemic circulation. Native whey and micellar casein are both dairy proteins that contain a similar amount of essential (EAA), but blood EAA levels increase faster and to a higher level after the consumption of whey protein. Differences in gastric emptying, digestion and absorption kinetics between micellar casein and native whey are the underlying factors. Nonetheless, micellar casein protein has been shown to protract MPS in humans. Despite the significant amount of information gained with respect to both of these protein sources, the effects of combinatorial formulations on the postprandial profile of amino acids appearing in the blood is less well known. The purpose of the present study is to determine post-ingestion aminoacidemia, glycemia, and insulinemia from a specially formulated dairy protein blend.

研究概览

地位

未知

条件

详细说明

Experimental approach:

8 participants will be included in this study. Each participant will consume the supplement only once in a randomized fashion during three separate visits and there will be approximately 1 week between each visit.

Standardized meal:

Participants will be provided a standardized diet one day prior to experimentation. When performing research involving human metabolism it is important that the participants be tested in a weight-stable state. Therefore, the investigators will estimate the participants resting energy expenditure using a widely reference prediction formula, known as the Harris-Benedict equation. This formula takes into account gender, body mass, height, age, and self-reported activity level. Once resting energy expenditure is calculated the investigators will provide each participant with a pre-packaged standardized diet for the day prior to the experiment that is designed to ensure a sufficient energy balance.

Dual Energy X-Ray Absorptiometry (DXA) Scans:

DXA scans will be used to determine the participants body composition. The DXA procedures use a small amount of radiation to determine how much fat, bone, and lean mass the participants have in their body. The procedure takes approximately seven minutes and involves the participants lying still on an open bed while the sensor passes over the participants body.

Arterialized blood sampling:

All blood sampling will be achieved through an intravenous indwelling cannula. This method provides the least trauma to the participant when repeated blood sampling is required and is convenient for the investigators. In theory, repeated needle sticks may stress the participant thereby increasing sympathetic nervous system activity, thus causing changes in metabolism. Additionally, another potential drawback from venous blood sampling is the influence by regional tissue specific metabolism, thereby making it difficult to interpret whole-body metabolism on the basis of metabolites measured in venous blood. Therefore, arterial blood sampling is deemed the ideal method for metabolic studies. Arterial cannulation, however, may be unethical for research purposes due to increased risk of complications, such as damage to the arterial wall, thrombosis, and clot formation, all of which may cause death. Arterializing the blood being sampled can be achieved through heating either the superficial antecubital vein or dorsal hand vein with a heating blanket or specialized heat box. By doing so, blood flow increases as a result of vasodilatation of vessels in the arms skeletal musculature, as well as arteriovenous anastomoses in skin. Due to the increased blood flow and negligible muscle mass at the hand and elbow, results in venous blood being similar in composition to an arterial sample. This method is a widely used surrogate for safe direct arterial blood sampling. Once arterialized blood samples are obtained they will be preserved and used in analyses. The investigators will utilize heating blankets (Theratherm Large Digital Moist Heat Pad [14" x 27"]) to arterialize the blood samples and an infrared thermometer (Nubee, NUB8380) to determine the skin temperature (45-68∘C) prior to drawing the participant's blood.

Per-protocol conditions will include:

Consumption of a standardized meal the evening prior to each trial and consistent exercise/activity 2d before each trial There will be ~1wk between trials (washout periods) Blood samples will be analyzed for plasma amino acids, glucose, and insulin.

Experimental Interventions (randomized order):

  1. Participants will consume a Low Protein Containing Breakfast (10% of the Acceptable Macronutrient Distribution Range according to the Food and Nutrition Board of the Institute of Medicine) and 2 hours later the participants will consume 17g of a leucine enriched whey protein- hydrolyzed whey protein-micellar casein blend (50:43:7 whey:hydrolyzed-whey:casein) containing 600 IU Vitamin D and 3.5g leucine
  2. Participants will consume a High Protein Containing Breakfast (25% of the Acceptable Macronutrient Distribution Range according to the Food and Nutrition Board of the Institute of Medicine)
  3. Participants will consume a Low Protein Containing Breakfast (10% of the Acceptable Macronutrient Distribution Range according to the Food and Nutrition Board of the Institute of Medicine)

Proteins were provided by Covance Laboratories, Inc. owned by Eurofins.

The whey protein and micellar casein are milk proteins derived from cow's milk. The participants will consume the 17g of protein contained in a semi-solid bar equal to ∼40g, which is the size of a typical sports recovery bar.

Sample size and data analyses:

The sample size was determined by a statistical power analysis (G*Power 3.1 software, version 3.1.9, 2014) that revealed a large effect size. This study was powered on the basis of previous studies. Thus, a total of 8 (n = 8/group) participants will be used in analyses. See Below:

Analysis: A priori: Compute required sample size ANOVA: Repeated measures, within-between interaction Input Effect size f = 0.5 α err prob = 0.05 Power (1-β err prob) = 0.95 Number of groups = 3 Number of measurements = 14 Corr. Among rep. measures = 0.5 Nonsphericity correction ε = 1 Output Noncentrality parameter ƛ = 63 Critical F = 1.6380186 Numerator df = 26 Denominator df = 78 Total sample = 9 Actual power = 0.997

研究类型

观察性的

注册 (实际的)

8

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario
      • Hamilton、Ontario、加拿大、L8S 4K1
        • Exercise Metabolism Research Laboratory, McMaster Univeristy

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 及以上 (年长者)

接受健康志愿者

不适用

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Healthy Older Adults

描述

Inclusion Criteria:

  • 8 participants will be included in this study. Each participant will consume the supplement only once in a randomized fashion during one of three separate visits and there will be approximately 1 week between each visit. In order to participate in this study, each participant must be male or female, 65 years or older (inclusive) and cannot be a smoker or user of tobacco products.

Exclusion Criteria:

  • The exclusion requirements for this study include the following conditions:

    • Take any analgesic or anti-inflammatory drugs(s), prescription or non-prescription, chronically will be excluded. However, a washout period of 4 weeks will be suitable for participation.
    • A history of neuromuscular problems or muscle and/or bone wasting diseases
    • Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires
    • Use medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Supplementation with Enriched Protein®
Participants will consume a low protein containing breakfast and 2 hours later will consume the enriched protein supplement
This product contains high quality bovine milk proteins enriched with additional leucine.
Low protein breakfast
No supplementation
High protein breakfast
No supplementation

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Easy-fast amino acid sample testing kit for gas chromatography mass spectrometry
大体时间:375 minutes
plasma amino acid concentrations
375 minutes

次要结果测量

结果测量
措施说明
大体时间
Hexokinase/G-6-PDH methodology
大体时间:375 minutes
plasma glucose concentrations
375 minutes
Chemiluminescent Microparticle Immunoassay
大体时间:375 minutes
plasma insulin concentrations
375 minutes
Visual Analog Scale Questionnaires for food sensory perception desire to eat
大体时间:Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for hunger
大体时间:Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for fullness
大体时间:Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for thirst
大体时间:Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for how much food could be eaten
大体时间:Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for liking or disliking of food
大体时间:Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for visual appeal
大体时间:Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for smell
大体时间:Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for taste
大体时间:Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for aftertaste
大体时间:Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for pleasantness
大体时间:Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Height in meters
大体时间:One measurement at baseline
Stadiometer
One measurement at baseline
Weight in kilograms
大体时间:One measurement at baseline
Physician scale
One measurement at baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年3月28日

初级完成 (实际的)

2019年12月1日

研究完成 (预期的)

2020年6月1日

研究注册日期

首次提交

2018年10月16日

首先提交符合 QC 标准的

2018年10月18日

首次发布 (实际的)

2018年10月19日

研究记录更新

最后更新发布 (实际的)

2020年2月7日

上次提交的符合 QC 标准的更新

2020年2月6日

最后验证

2020年2月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2502

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Enriched Protein®的临床试验

3
订阅